Jubilant Pharmova Appoints Daniel J O''Connor as CEO

1 Minute Read Listen to Article
Share:    

Dec 02, 2025 15:31

x
Jubilant Pharmova names Daniel J O''Connor as CEO of its proprietary novel drugs business. He brings 30+ years of leadership experience.
Jubilant Pharmova Appoints Daniel J O''Connor as CEO
New Delhi, Dec 2 (PTI) Jubilant Pharmova on Tuesday said it has appointed Daniel J O'Connor as the CEO of its proprietary novel drugs business.

O'Connor brings more than 30 years of leadership experience in biotechnology and oncology, with a proven record of creating value around differentiated, IP-rich platforms, the company said in a statement.


Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation, culminating in its successful acquisition, it added.

"We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications," its chairman Shyam S Bhartia said.

Jubilant Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback